BOSTON, April 10, 2025--(BUSINESS WIRE)--Syntis Bio, Inc. (Syntis), a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes and rare diseases, today announced ...
Syntis Bio Inc. has presented preclinical data regarding their antiobesity compound SYNT-101 in the preclinical setting. SYNT-101 is a novel oral compound developed to treat obesity and related ...
BOSTON--(BUSINESS WIRE)--Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results